Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

142 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2021 Jan 9:105422. doi: 10.1016/j.phrs.2021.105422. Online ahead of print. Pharmacol Res. 2021. PMID: 33434619 Review.
NIH funding trends to US medical schools from 2009 to 2018.
Noble P, Ten Eyck P, Roskoski R Jr, Jackson JB. Noble P, et al. Among authors: roskoski r jr. PLoS One. 2020 Jun 1;15(6):e0233367. doi: 10.1371/journal.pone.0233367. eCollection 2020. PLoS One. 2020. PMID: 32480400 Free PMC article.
The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2020 May;155:104725. doi: 10.1016/j.phrs.2020.104725. Epub 2020 Feb 25. Pharmacol Res. 2020. PMID: 32109580 Review.
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2020 Feb;152:104609. doi: 10.1016/j.phrs.2019.104609. Epub 2019 Dec 17. Pharmacol Res. 2020. PMID: 31862477 Review.
The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2020 Jan;151:104567. doi: 10.1016/j.phrs.2019.104567. Epub 2019 Nov 23. Pharmacol Res. 2020. PMID: 31770593 Review.
Corrigendum to "Targeting ERK1/2 protein-serine/threonine kinases in human cancers" [Pharmcol. Res. 142 (2019) 151-168].
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2019 May;143:206. doi: 10.1016/j.phrs.2019.03.019. Epub 2019 Apr 3. Pharmacol Res. 2019. PMID: 30952557 No abstract available.
Properties of FDA-approved small molecule protein kinase inhibitors.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2019 Jun;144:19-50. doi: 10.1016/j.phrs.2019.03.006. Epub 2019 Mar 13. Pharmacol Res. 2019. PMID: 30877063 Review.
Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2019 Apr;142:151-168. doi: 10.1016/j.phrs.2019.01.039. Epub 2019 Feb 20. Pharmacol Res. 2019. PMID: 30794926 Review.
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2019 Jan;139:471-488. doi: 10.1016/j.phrs.2018.11.035. Epub 2018 Nov 30. Pharmacol Res. 2019. PMID: 30508677 Review.
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2019 Jan;139:395-411. doi: 10.1016/j.phrs.2018.11.014. Epub 2018 Nov 27. Pharmacol Res. 2019. PMID: 30500458 Review.
142 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback